logo-loader
HealthPharma & Biotech
Orthocell Ltd

Orthocell publishes positive pre-clinical trial study for CelGro nerve repair

Orthocell Ltd (ASX:OCC) managing director Paul Anderson updates Proactive Investors on the company’s positive pre-clinical study results for CelGro nerve regenerative treatment.

The results validate claims that the technique can deliver higher quality nerve repair, compared to existing methods.

Results also showed the use of CelGro in rats restored nerve fibres to complete regeneration, with these being indistinguishable from normal nerve histology.

Quick facts: Orthocell Ltd

Price: $0.43

Market: ASX
Market Cap: $65.58 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'May only be a matter of time' before Uranium price recovery with...

Mining Capital's Alastair Ford discusses the planned slow down in production from Kazatomprom (LON:KAP). The miner's looking to cut output from its Kazakh mines by around 20% through to 2021. He says that extends the timeframe of its previous production curtailment by a further year, and...

13 hours, 18 minutes ago

2 min read